| Bioactivity | Upacicalcet sodium is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT)[1]. |
| Target | calcium-sensing receptors |
| Name | Upacicalcet sodium |
| CAS | 2052969-18-1 |
| Formula | C11H13ClN3NaO6S |
| Molar Mass | 373.75 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Hoy SM. Upacicalcet: First Approval. Drugs. 2021;81(13):1593-1596. |
Upacicalcet sodium
CAS: 2052969-18-1 F: C11H13ClN3NaO6S W: 373.75
Upacicalcet sodium is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.